Lantheus to Present Florbetaben F 18 Data at CTAD 2025
Lantheus Holdings, Inc. (LNTH)
Last lantheus holdings, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.lantheus.com/investor-relations
Company Research
Source: GlobeNewswire
BEDFORD, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced the presentation of new florbetaben F18 data at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) 2025 conference, taking place December 1-4, in San Diego, CA. Presentation details are as follows: Poster Presentation Date & Time: Wednesday, December 3, 2025; 7:15 AM – 5:30 PM PT Session Number: 06 Session Title: Clinical Trials: Imaging Poster Title: Florbetaben binding to amyloid plaques is unaffected by amyloid-targeting antibodies lecanemab and donanemab Poster Number: P184 Presenter: Marianne Chapleau, Life Molecular Imaging About Neuraceq® (florbetaben F 18 injection) Indication Neuraceq is indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density
Show less
Read more
Impact Snapshot
Event Time:
LNTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LNTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LNTH alerts
High impacting Lantheus Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
LNTH
News
- Lantheus (LNTH): Buy, Sell, or Hold Post Q3 Earnings? [Yahoo! Finance]Yahoo! Finance
- The Bottom Fishing Club - Lantheus Holdings: Interesting Buy Momentum Supporting Price [Seeking Alpha]Seeking Alpha
- Lantheus, Enovis, Evolent Health, Repligen, and Corcept Shares Are Soaring, What You Need To Know [Yahoo! Finance]Yahoo! Finance
- Investors who lost money on Lantheus Holdings, Inc. (LNTH) should contact The Gross Law Firm about pending Class Action - LNTHGlobeNewswire
- Portnoy Law Firm Announces Class Action on Behalf of Lantheus Holdings, Inc. InvestorsGlobeNewswire
LNTH
Earnings
- 11/6/25 - Beat
LNTH
Sec Filings
- 11/26/25 - Form 144
- 11/19/25 - Form 4
- 11/14/25 - Form 144
- LNTH's page on the SEC website